Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

The Trump administration struck a new deal with Eli Lilly to offer the drug maker’s weight loss drug to some Medicare ...

Trump deals with Eli Lilly and Novo Nordisk increase access to obesity drugs, providing a safe, convenient way to slim down ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...